These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11234911)

  • 1. Short-term effects of olanzapine in Huntington disease.
    Squitieri F; Cannella M; Porcellini A; Brusa L; Simonelli M; Ruggieri S
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):69-72. PubMed ID: 11234911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine for Huntington's disease: an open label study.
    Bonelli RM; Mahnert FA; Niederwieser G
    Clin Neuropharmacol; 2002; 25(5):263-5. PubMed ID: 12410058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
    Poyurovsky M; Dorfman-Etrog P; Hermesh H; Munitz H; Tollefson GD; Weizman A
    Int Clin Psychopharmacol; 2000 May; 15(3):169-73. PubMed ID: 10870875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
    Baker RW; Ames D; Umbricht DS; Chengappa KN; Schooler NR
    Psychopharmacol Bull; 1996; 32(1):89-93. PubMed ID: 8927681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month outcomes for patients who switched to olanzapine treatment.
    Noordsy DL; O'Keefe C; Mueser KT; Xie H
    Psychiatr Serv; 2001 Apr; 52(4):501-7. PubMed ID: 11274497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine and Huntington's disease.
    Bogelman G; Hirschmann S; Modai I
    J Clin Psychopharmacol; 2001 Apr; 21(2):245-6. PubMed ID: 11270928
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of Huntington's disease with olanzapine and valproate.
    Grove VE; Quintanilla J; DeVaney GT
    N Engl J Med; 2000 Sep; 343(13):973-4. PubMed ID: 11012330
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Tribl GG; Költringer P
    Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of olanzapine for movement disorder in Huntington's disease: a first case report.
    Dipple HC
    J Neurol Neurosurg Psychiatry; 1999 Jul; 67(1):123-4. PubMed ID: 10454874
    [No Abstract]   [Full Text] [Related]  

  • 10. Olanzapine in Huntington's disease.
    Paleacu D; Anca M; Giladi N
    Acta Neurol Scand; 2002 Jun; 105(6):441-4. PubMed ID: 12027832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.
    Benazzi F
    J Clin Psychopharmacol; 2002 Aug; 22(4):438-9. PubMed ID: 12172349
    [No Abstract]   [Full Text] [Related]  

  • 12. [Olanzapine improves chorea in patients with Huntington's disease].
    Jiménez-Jiménez FJ; de Toledo M; Puertas I; Barón M; Zurdo M; Barcenilla B
    Rev Neurol; 2002 Sep 16-30; 35(6):524-5. PubMed ID: 12389168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms.
    Martényi F; Metcalfe S; Schausberger B; Dossenbach MR
    J Clin Psychiatry; 2001; 62 Suppl 2():25-7. PubMed ID: 11232748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine treatment of obsessive-compulsive disorder.
    Degner D; Bleich S; Kornhuber J; Rüther E
    Can J Psychiatry; 2000 May; 45(4):393. PubMed ID: 10813075
    [No Abstract]   [Full Text] [Related]  

  • 16. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
    Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V
    Am J Psychiatry; 1999 May; 156(5):702-9. PubMed ID: 10327902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.
    Grant JE
    J Clin Psychiatry; 2001 Apr; 62(4):297-8. PubMed ID: 11379848
    [No Abstract]   [Full Text] [Related]  

  • 18. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.
    Etchebehere EC; Lima MC; Passos W; Maciel Júnior JA; Santos AO; Ramos CD; Camargo EE
    Arq Neuropsiquiatr; 1999 Sep; 57(3B):863-6. PubMed ID: 10751925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.
    Ishigooka J; Murasaki M; Miura S
    Psychiatry Clin Neurosci; 2000 Aug; 54(4):467-78. PubMed ID: 10997865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.